As the U.S. stock market experiences a pullback with investors assessing CPI inflation data and major bank earnings, attention turns to alternative investment opportunities like penny stocks. Often considered an outdated term, penny stocks still hold relevance as they represent smaller or newer companies that can offer growth potential at lower price points. When these companies are backed by strong financial fundamentals, they present intriguing options for investors seeking hidden value in today's market landscape.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Dingdong (Cayman) (DDL)	$3.03	$636.49M	✅ 3 ⚠️ 1 View Analysis >
Waterdrop (WDH)	$1.88	$669.08M	✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS)	$0.8738	$149.44M	✅ 4 ⚠️ 1 View Analysis >
LexinFintech Holdings (LX)	$3.14	$528.35M	✅ 4 ⚠️ 2 View Analysis >
CI&T (CINT)	$4.56	$625.72M	✅ 5 ⚠️ 0 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 1 ⚠️ 5 View Analysis >
Cricut (CRCT)	$4.92	$1.04B	✅ 2 ⚠️ 2 View Analysis >
VAALCO Energy (EGY)	$3.72	$380.54M	✅ 2 ⚠️ 3 View Analysis >
BAB (BABB)	$0.9201	$6.68M	✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)	$4.04	$91.53M	✅ 3 ⚠️ 2 View Analysis >

Here we highlight a subset of our preferred stocks from the screener.

AC Immune (ACIU)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and products for neurodegenerative diseases related to protein misfolding, with a market cap of $348.28 million.

Operations: The company's revenue segment is primarily focused on discovering and developing therapeutic and diagnostic products, generating CHF 4.37 million.

Market Cap: $348.28M

AC Immune SA, a clinical-stage biopharmaceutical company, is navigating the penny stock landscape with a market cap of $348.28 million and recent developments in its pipeline. The company remains pre-revenue, reporting CHF 0.939 million in third-quarter revenue for 2025, significantly down from the previous year. Despite this, AC Immune's financial position is relatively stable with short-term assets exceeding liabilities and no debt on its books. Recent positive interim results from a Phase 2 trial of its anti-alpha-synuclein immunotherapy for Parkinson’s disease highlight potential therapeutic advancements and have garnered attention within the biotech community.

111 (YI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: 111, Inc., along with its subsidiaries, operates an integrated online and offline healthcare platform in the People's Republic of China, with a market cap of $31.64 million.

Operations: The company's revenue is derived entirely from its operations within the People's Republic of China, amounting to CN¥13.58 billion.

Market Cap: $31.64M

111, Inc. operates within the penny stock arena with a market cap of $31.64 million, focusing on an integrated healthcare platform in China. Despite being unprofitable, it has reduced losses by 28.1% annually over five years and maintains a stable cash runway exceeding three years due to positive free cash flow growth of 34.1% per year. Its management and board are experienced, with average tenures over seven years each. Recent earnings show decreased sales but narrowed net losses compared to the previous year, indicating potential operational improvements amidst challenges in revenue generation and profitability stabilization efforts.

Seer (SEER)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Seer, Inc. is a life sciences company focused on developing and commercializing products to decode the biology of the proteome, with a market cap of approximately $109.69 million.

Operations: The company generates its revenue primarily from the biotechnology sector, specifically targeting startups, with earnings of $16.38 million.

Market Cap: $109.69M

Seer, Inc., with a market cap of US$109.69 million, is navigating the penny stock landscape by focusing on proteomics technology through its Proteograph Product Suite. Despite being unprofitable and experiencing increased losses over five years, Seer has no debt and maintains a stable cash runway for over three years. Recent product-related announcements highlight the company's role in advancing proteogenomics research, which could bolster its position in biotechnology. Although revenue growth is projected at 29.28% annually, significant insider selling poses a concern for investors assessing long-term stability amidst ongoing financial challenges and strategic developments.

Where To Now?

• Click here to access our complete index of 337 US Penny Stocks.
• Ready To Venture Into Other Investment Styles? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.